Skip to main content
PortfolioPoseida Therapeutics, Inc.

Poseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer

By May 20, 2020March 15th, 2021No Comments